Dec 21 2009
On December 15, 2009, Repros Therapeutics Inc. (NasdaqGM:RPRX) received
notification from NASDAQ that it has not regained compliance with NASDAQ
Listing Rules 5450(b)(2)(C) and 5450(b)(1). The first rule applies to
the market value of publicly held shares and the latter is the
requirement of a minimum of a $1 share price. The Company has until June
14, 2010 to rectify the $1 share price deficiency assuming that the
Company’s appeal to remain listed is granted. Repros appealed the
listing deficiency associated with Rule 5450 (b)(2)(C) in early December
and the Company awaits the decision of the NASDAQ Listing Qualifications
Panel. As part of the Repros appeal the Company requested its securities
be moved to the NASDAQ Capital Market. There can be no assurance that
the appeal will be successful thereby allowing Repros to continue to
trade on a NASDAQ market.